Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link . After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

The webcast audio will be available via this link .

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com .

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer's disease patients. For more information, visit www.acumenpharm.com .

Investors:
Alex Braun
abraun@acumenpharm.com

Media:
AcumenPR@westwicke.com



Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ABOS:US
The Conversation (0)

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

  • Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024

  • Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024

  • Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027

  • Company to host conference call and webcast today at 8:00 a.m. ET

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2024 and provided a business update.

"In the first quarter, our team remained laser-focused on the initiation of ALTITUDE-AD, our Phase 2 study investigating the efficacy and safety of sabirnetug for the treatment of early AD. We announced the first patient dosed in this study just last week. We are encouraged by the level of investigator interest in the potential of sabirnetug to offer a best-in-class therapeutic profile for patients, which is a testament to our strong Phase 1 data package and the relationships our team has built with clinical sites," Daniel O'Connell, Chief Executive Officer of Acumen. "We continue to expect to initiate a Phase 1 study with a subcutaneous form of sabirnetug in mid-2024 in an effort to extend the product profile and offer administration optionality for patients. We remain committed to delivering on our strategic priority to advance the clinical development of sabirnetug efficiently and thoughtfully."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

  • Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024

  • Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024

  • Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027

  • Company to host conference call and webcast today at 8:00 a.m. ET

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2024 and provided a business update.

"In the first quarter, our team remained laser-focused on the initiation of ALTITUDE-AD, our Phase 2 study investigating the efficacy and safety of sabirnetug for the treatment of early AD. We announced the first patient dosed in this study just last week. We are encouraged by the level of investigator interest in the potential of sabirnetug to offer a best-in-class therapeutic profile for patients, which is a testament to our strong Phase 1 data package and the relationships our team has built with clinical sites," Daniel O'Connell, Chief Executive Officer of Acumen. "We continue to expect to initiate a Phase 1 study with a subcutaneous form of sabirnetug in mid-2024 in an effort to extend the product profile and offer administration optionality for patients. We remain committed to delivering on our strategic priority to advance the clinical development of sabirnetug efficiently and thoughtfully."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

  • Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024

  • Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024

  • Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027

  • Company to host conference call and webcast today at 8:00 a.m. ET

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2024 and provided a business update.

"In the first quarter, our team remained laser-focused on the initiation of ALTITUDE-AD, our Phase 2 study investigating the efficacy and safety of sabirnetug for the treatment of early AD. We announced the first patient dosed in this study just last week. We are encouraged by the level of investigator interest in the potential of sabirnetug to offer a best-in-class therapeutic profile for patients, which is a testament to our strong Phase 1 data package and the relationships our team has built with clinical sites," Daniel O'Connell, Chief Executive Officer of Acumen. "We continue to expect to initiate a Phase 1 study with a subcutaneous form of sabirnetug in mid-2024 in an effort to extend the product profile and offer administration optionality for patients. We remain committed to delivering on our strategic priority to advance the clinical development of sabirnetug efficiently and thoughtfully."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2 nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2 nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Falco Announces Resignation of Board Member

Falco Announces Resignation of Board Member

Falco Resources Ltd. (TSX-V: FPC) ( "Falco" or the " Corporation" ) announced today that Mr. Claude Dufresne has resigned as a member of the Board of Directors so that he may focus his efforts on other professional duties.

The Board of Directors would like to thank Mr. Dufresne for his contribution over the past few years and wish him well in his future endeavors.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Bold Options Claims in Ring of Fire Region

Bold Options Claims in Ring of Fire Region

Bold Ventures Inc. (TSXV:BOL) (the "Company" or "Bold") is pleased to announce that it has signed an option agreement (the "Agreement") to option a 100% interest in two claim groups (the "Optioned Claims") to an arms-length party (the "Optionee"). The claims are located in the Ring of Fire Region. The Optioned Claims were staked during a regional airborne Electromagnetic and Magnetic survey flown in 2013 for Bold Ventures and its co-Venturer, a subsidiary of Dundee Resources. The survey resulted in over 14 claim groups being staked at various times over two campaigns. The Optioned Claims have a combined area of approximately 2,595 acres (1,050 hectares) and comprise approximately 90 claim units. The Optioned Claims have seen very little exploration work in the past

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
WESTERN COPPER AND GOLD ANNOUNCES VOTING RESULTS FROM ANNUAL SHAREHOLDERS' MEETING

WESTERN COPPER AND GOLD ANNOUNCES VOTING RESULTS FROM ANNUAL SHAREHOLDERS' MEETING

western copper and gold corporation ("Western" or the "Company") (TSX: WRN) (NYSE American: WRN) announces the voting results from the Company's Annual General and Special Meeting ("AGM") held on June 27, 2024.

Western Copper and Gold Corporation logo (CNW Group/Western Copper and Gold Corporation)

A total of 101,875,249 common shares were represented at the AGM, representing 51.92% of the votes attached to all outstanding common shares as at the record date.

Shareholders voted in favour of setting the number of directors at seven (7) and elected all directors, as follows:

Director

Votes For

% For

Votes Withheld

% Withheld

Robert Chausse

90,608,768

99.84 %

165,930

0.16 %

Tara Christie

82,647,749

90.20 %

8,979,661

9.80 %

Sandeep Singh

91,295,444

99.64 %

331,966

0.36 %

Raymond Threlkeld

90,876,101

98.85 %

1,018,642

1.11 %

Michael Vitton

87,843,574

95.87 %

3,783,836

4.13 %

Bill Williams

83,566,754

91.20 %

8,060,656

8.80 %

Klaus Zeitler

83,576,626

91.21 %

8,050,785

8.79 %

Shareholders also approved:  (i) the appointment of PricewaterhouseCoopers LLP as auditors of the Company and authorized the directors to set their remuneration, (ii) unallocated stock options under the Company's stock option plan, (iii) unallocated rights under the Company's deferred share unit plan, (iv) unallocated rights under the Company's restricted share unit plan.

The Company's report of voting results will be available on SEDAR ( www.sedar.com ), EDGAR ( www.sec.gov/edgar.shtml ), and on the Company's website.

ABOUT western copper and gold corporation

western copper and gold corporation is developing the Casino Project, Canada's premier copper-gold mine in the Yukon Territory and one of the most economic greenfield copper-gold mining projects in the world.

The Company is committed to working collaboratively with our First Nations and local communities to progress the Casino project, using internationally recognized responsible mining technologies and practices.  For more information, visit www.westerncopperandgold.com .

On behalf of the board,

"Sandeep Singh"

Sandeep Singh
Chief Executive Officer
western copper and gold corporation

SOURCE western copper and gold corporation

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2024/27/c2084.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
FALCO ANNOUNCES CLOSING OF FIRST TRANCHE OF BROKERED PRIVATE PLACEMENT

FALCO ANNOUNCES CLOSING OF FIRST TRANCHE OF BROKERED PRIVATE PLACEMENT

TSX.V - FPC

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Forte Minerals Corp. Closes Oversubscribed Private Placement Offering

Forte Minerals Corp. Closes Oversubscribed Private Placement Offering

(Not for distribution to United States newswire services or for dissemination in the United States of America)

Forte Minerals Corp. ("Forte" or the "Company") (CSE:CUAU)(OTCQB:FOMNF)(Frankfurt:2OA), is pleased to announce the closing of its previously announced non-brokered private placement (the "Offering") (see press release dated June 5, 2024). The Offering was initially set for 7,500,000 units but, due to high demand, was oversubscribed, resulting in the issuance of 8,953,000 units at a price of CAD $0.20 per unit for aggregate gross proceeds of CAD $1,790,600

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Aston Bay Announces Planned Exploration Program at its Epworth Sediment Hosted Copper-Silver-Zinc-Cobalt Project, Nunavut, Canada

Aston Bay Announces Planned Exploration Program at its Epworth Sediment Hosted Copper-Silver-Zinc-Cobalt Project, Nunavut, Canada

Airborne geophysics, structural mapping, and sampling to define drill targets

Aston Bay Holdings Ltd. (TSX-V:BAY)(OTCQB:ATBHF) (the "Company" or "Aston Bay") is pleased to announce the proposed summer 2024 exploration program at its Epworth sediment hosted copper-silver-zinc-cobalt project located 80 kilometres ("km") southeast of Kugluktuk in Nunavut, Canada

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

Ă—